Email updates

Keep up to date with the latest news and content from WAO Journal and BioMed Central.

Open Access Open Badges Reviews

Eosinophils in Chronic Urticaria: Supporting or Leading Actors?

Riccardo Asero1*, Massimo Cugno2 and Alberto Tedeschi3

Author Affiliations

1 Allergy Unit, Clinica San Carlo, Paderno Dugnano (Milan), Italy

2 Department of Internal Medicine, University of Milan and IRCCS Foundation Maggiore Hospital, Mangiagalli and Regina Elena, Milan, Italy

3 Allergy and Clinical Immunology Unit, IRCCS Foundation Maggiore Hospital, Mangiagalli and Regina Elena, Milan, Italy

For all author emails, please log on.

World Allergy Organization Journal 2009, 2:213-217  doi:10.1097/WOX.0b013e3181bb965f

The electronic version of this article is the complete one and can be found online at: http://www.waojournal.org/content/2/9/213


Published:15 September 2009

© 2009 World Allergy Organization; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Although their number may be increased in skin lesions, eosinophils have been rather neglected as possible participants to the pathogenesis of chronic urticaria because of the absence of peripheral eosinophilia in patients with this disease. However, recent data suggest a potentially relevant role played by activated eosinophils both in triggering the tissue factor pathway of coagulation cascade and as a source of vascular endothelial growth factor. Such phenomena seem more pronounced in patients showing a more severe disease. The present study will rediscuss the potential role of this cell line in chronic urticaria in the light of these recent observations.

Keywords:
chronic urticaria; mastcells; eosinophils; VEGF; tissue factor

Introduction

Chronic urticaria (CU), defined as the occurrence of spontaneous wheals, with or without angioedema, for more than 6 weeks is a rather frequent disorder. As in most other types of urticaria, the pathophysiologic basis of CU is unquestionably the recurrent degranulation of dermal mast cells and of basophils. Mast cells and, to a lesser extent, basophils, are generally regarded as the main effectors of this disease. However, the events occurring upstream and eventually resulting in histamine release from these cells are partially defined. Studies carried out during the last 2 decades have led to the detection of functional autoantibodies to the high affinity IgE receptor, FcεRI, or to IgE that are able to cause degranulation and histamine release from both mast cells and basophils [1-4]. Complement plays a relevant role in this process by enhancing histamine release induced by FcεRI autoantibodies [5,6]. However, it is generally agreed that autoantibodies to FcεRI or to IgE can be detected in less than 50% of CU patients. Furthermore, there is increasing evidence that autoantibodies and in vivo autoreactivity can also be detected in other conditions and in healthy subjects [7-10]. All this means that the factors triggering histamine release in chronic urticaria remain a mystery in many cases. The reported efficacy of omalizumab in patients with refractory CU either with or without detectable autoantibodies [11-15] and the observed, although not totally specific, inhibitory effect of heparin on autoantibody-triggered histamine release from basophils in vitro,[16,17] suggest a common final pathway in histamine release, irrespective of the histamine-releasing factor involved.

Histology of CU

It is generally accepted that the histologic picture is more or less the same in all patients with CU irrespective of the presence or absence of autoantibodies. A perivascular infiltrate of CD4+ lymphocytes is always present [18]. Infiltrating cells have the characteristics of both TH1 and TH2 cells; increased numbers of intradermal CD3, CD4, CD8-positive T cells have been detected with a TH0 cytokine profile. Neutrophils and a variable degree of eosinophils are also present [19,20]. Eosinophils are often activated, particularly in patients without autoantibodies,[20] and major basic protein can be measured in urticaria lesion even when eosinophils are not detected [21]. The number of mast cells has been reported as increased in urticaria lesions [18] although this finding has not been confirmed by more recent studies,[19,22] and some basophil infiltration is also observed. It has been suggested that the infiltrate is similar to that of an allergy late-phase reaction [23,24].

Interestingly, the eosinophil-derived major basic protein has been identified in autologous serum skin test site biopsies, along with eosinophil infiltration [25]. The immune mechanisms and the main effector cells involved in chronic urticaria are shown in Figure 1.

thumbnailFigure 1. Immune mechanisms and main effector cells involved in chronic urticaria. A, Mast cells are activated either by autoantibodies to FeεRI or IgE and/or by other histamine releasing factors and release several mediators (histamine, leukotrienes, VEGF) that concur to produce the marked vasodilation that stands at the basis of both wheal-and flare reaction and angioedema. Some mediators and chemokines released by mast cells can recruit and activate eosinophils that in turn release inflammatory mediators and produce tissue factor, the main initiator of the extrinsic pathway of the coagulation cascade. The major basic protein released by eosinophils can induce mast cell degranulation. B, Eosinophils can be activated either directly by autoantibodies against the low affinity IgE receptor or indirectly by mast-cell derived mediators. C, Activated T-cells can induce mast cell degranulation by cell-to-cell contact. This process leads to the formation and release of cytokines such as TNF-α that has the capacity to induce gene expression in mast cells by an autocrine mechanism. ECP, eosinophil cationic protein; GM-CSF, granulocyte-monocyte colony-stimulating factor; MBP, major basic protein; PAF, platelet-activating factor; SCF, stem cell factor.

Who Activates Mast Cells When Autoantibodies are not Present?

During the last 5 years, our group has spent some time and effort trying to respond to this question by measuring the circulating levels of some mediators potentially able to induce mast-cell degranulation and histamine release. In view of the constant absence of blood eosinophilia in CU, we measured serum levels of some substances not specifically related with eosinophils, namely stem cell factor,[26] substance P,[27] and interleukin (IL)-18 [28]. However, the concentration of these mediators did not significantly differ between patients and controls. Recently, we have been luckier when, based on the observation of a higher prevalence of positive autologous plasma skin test over autologous serum skin test, we started looking at the coagulation cascade and were able to demonstrate that CU is characterized by thrombin generation,[29] which is the result of an activation of the tissue pathway of blood coagulation [30,31]. Notably, studies in animal models have shown that thrombin is able to induce mastcell degranulation,[32] and in rat mast cell populations, the response to thrombin is equipotent with FcεRI-mediated activation [33]. Thus (although evidence that thrombin induces mast cells degranulation in humans is still missing), thrombin might be a candidate mast-cell activating factor, at least in patients whose sera don't contain autoantibodies and show an activation of coagulation cascade. One good question is if thrombin activates all mast cells, why do we see just skin mast cell activation in CU? In other words, why is there skin selectivity in CU? In effect, there are studies showing that in CU patients there is bronchial hyper-responsiveness and, sometimes, frank asthma [34,35].

Eosinophils as Activators of the Coagulation Cascade and as Source of Vegf in Chronic Urticaria (Figure 2)

Interestingly, although the role of other cells cannot be ruled out, investigating further the activation of the coagulation cascade, we found that the cells expressing tissue factor in chronic urticaria, and hence triggering the activation of the extrinsic pathway, are eosinophils [36]. In fact, immunohistochemical experiments showed that tissue factor colocalized with eosinophil cationic protein, a classic cell marker of eosinophils. These findings highlight the importance of eosinophils in chronic urticaria as a source of tissue factor, in keeping with recent studies showing that eosinophils store tissue factor and rapidly transfer it to the cell membrane during activation [37]. The strong expression of tissue factor in chronic urticaria lesional skin may be because of eosinophil activation, even if patients with chronic urticaria do not show peripheral eosinophilia, probably because tissue factor facilitates the early transendothelial migration of the eosinophils [37]. It is interesting to note that eosinophils in chronic urticaria may be activated both by direct and indirect mechanisms. In a single, hitherto unconfirmed, study autoantibodies directed against CD23, the low-affinity IgE receptor located on eosinophil membrane, have been detected in about 65% of chronic urticaria patients. These autoantibodies can activate eosinophils inducing the release of major basic protein, which in turn causes mast cell degranulation [38]. In addition, eosinophil involvement might be secondary to the mast cell activation caused by anti-FcεRI and anti-IgE autoantibodies or other histamine-releasing factors. It has been demonstrated that several mediators and cytokines released by activated mast cells can recruit and stimulate eosinophils. Among others, mast cells represent an important source of IL-5, tumor necrosis factor (TNF)-α, platelet-activating factor and eotaxin, molecules that can exert potent chemotactic and stimulating activities on eosinophils [39,40].

thumbnailFigure 2. Activation of the extrinsic pathway of the coagulation cascade by eosinophil-derived tissue factor in patients with chronic urticaria. Eosinophils produce and store tissue factor (blue triangles), and rapidly transfer it to the cell membrane during activation. Activation of the coagulation cascade and fibrinolysis in patients with chronic urticaria is demonstrated by the increased plasma levels of the prothrombin fragment F1+2 and D-dimer (indicated by red arrows).

One further recent observation is that patients with CU show a significant increase of vascular endothelial growth factor (VEGF) [41]. VEGF is the most potent regulator of angiogenesis presently known, and one of the major mediators of vascular permeability; furthermore, it exerts a vasodilator effect through an increase of nitric oxide production by endothelial cells [42,43]. Notably, eosinophils are the main source of VEGF in CU as well,[41] in agreement with the in vitro observations that human peripheral blood eosinophils have the capacity to induce angiogenesis [44]. All these findings clearly suggest that eosinophils might play a role in chronic urticaria.

Who is Activating Whom?

As reviewed above, it seems rather clear that both mast cells and eosinophils are activated in CU. Who is the one that starts all the process? Is eosinophil activation the result of mast cell-derived mediators release or are eosinophils themselves the cause of mast cell activation and subsequent histamine release?

It cannot be excluded that the leading actor may change in different subsets of patients. In patients showing circulating FcεRI and anti-IgE autoantibodies it is very likely that the main actor is the mast cell whereas in other patients showing only anti-FcεRII autoantibodies such role might be played by eosinophils. Finally, it cannot be excluded that T cells, which have been found in chronic urticaria lesional skin, also play a relevant role, possibly by activating the mast cells via a cell-to-cell contact. In fact, it has been demonstrated that T cells can activate mast cells by cell-to-cell contact, thus provoking the release of cytokines and inflammatory mediators such as histamine, TNF-α and matrix metalloproteinase 9 [45,46]. Furthermore, an aberrant signaling through the p21Ras pathway has been found in peripheral blood mono-nuclear cells of patients with chronic urticaria, a finding that is in agreement with lymphocyte activation and supports the autoimmune basis of the disease [47]. Finally, the clinical response of chronic urticaria to corticosteroid treatment suggests to the importance of the cellular infiltrate (T cells, eosinophils, or even basophils) because mast cells tend to be steroid-resistant.

References

  1. Grattan CEH, Francis DM, Hide M, Greaves MW: Detection of circulating histamine releasing autoantibodies with functional properties of anti IgE in chronic urticaria.

    Clin Exp Allergy 1991, 21:695-704. PubMed Abstract | Publisher Full Text OpenURL

  2. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria.

    N Engl J Med 1993, 328:1599-1604. PubMed Abstract | Publisher Full Text OpenURL

  3. Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, et al.: Serum IgG autoantibodies directed against the alpha chain of FcεRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?

    J Clin Invest 1995, 96:2606-2612. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  4. Ferrer M, Kinet JP, Kaplan AP: Comparative studies of functional and binding assays for IgG anti-FcεRIaα (α-subunit).

    J Allergy Clin Immunol 1998, 101:672-676. PubMed Abstract | Publisher Full Text OpenURL

  5. Ferrer M, Nakazawa K, Kaplan AP: Complement dependence of histamine release in chronic urticaria.

    J Allergy Clin Immunol 1999, 104:169-172. PubMed Abstract | Publisher Full Text OpenURL

  6. Kikuchi Y, Kaplan AP: A role for C5a in augmenting IgE-dependent histamine release from basophils in chronic urticaria.

    J Allergy Clin Immunol 2002, 109:114-118. PubMed Abstract | Publisher Full Text OpenURL

  7. Mari A: Allergy-like asthma and rhinitis. A cross-sectional survey of a respiratory cohort and a diagnostic approach using the autologous serum skin test.

    Int Arch Allergy Immunol 2004, 133:29-39. PubMed Abstract | Publisher Full Text OpenURL

  8. Guttman-Yassky E, Bergman R, Maor C, Mamorsky M, Pollack S, Shahar E: The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals.

    J Eur Acad Dermatol Venereol 2007, 21:35-39. PubMed Abstract | Publisher Full Text OpenURL

  9. Eckman JA, Hamilton RG, Saini SS: Independent evaluation of a commercial test for "autoimmune" urticaria in normal and chronic urticaria subjects.

    J Invest Dermatol 2009, 129:1584-1586. PubMed Abstract | Publisher Full Text OpenURL

  10. Taskapan O, Kutlu A, Karabudak O: Evaluation of autologous serum skin test results in patients with chronic idiopathic urticaria, allergic/ non-allergic asthma or rhinitis and healthy people.

    Clin Exp Dermatol 2008, 33:754-758. PubMed Abstract | Publisher Full Text OpenURL

  11. Spector SL, Tan RA: Effect of omalizumab on patients with chronic urticaria.

    Ann Allergy Asthma Immunol 2007, 99:190-193. PubMed Abstract | Publisher Full Text OpenURL

  12. Sands MF, Blume JW, Schwartz SA: Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab.

    J Allergy Clin Immunol 2007, 120:979-981. PubMed Abstract | Publisher Full Text OpenURL

  13. Godse KV: Omalizumab in severe chronic urticaria.

    Indian J Dermatol Venereol Leprol 2008, 74:157-158. PubMed Abstract | Publisher Full Text OpenURL

  14. Sheikh J: Effect of omalizumab on patients with chronic urticaria: issues with the determination of autoimmune urticaria.

    Ann Allergy Asthma Immunol 2008, 100:88-89. PubMed Abstract | Publisher Full Text OpenURL

  15. Dreyfus DH: Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema.

    Ann Allergy Asthma Immunol 2008, 100:624-625. PubMed Abstract | Publisher Full Text OpenURL

  16. Fagiolo U, Cancian M, Bertollo L, Peserico A, Amadori A: Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria.

    J Allergy Clin Immunol 1999, 103:1143-1147. PubMed Abstract | Publisher Full Text OpenURL

  17. Asero R, Tedeschi A, Lorini M, Salimbeni R, Zanoletti T, Miadonna A: Chronic urticaria: novel clinical and serological aspects.

    Clin Exp Allergy 2001, 31:1105-1110. PubMed Abstract | Publisher Full Text OpenURL

  18. Elias J, Boss E, Kaplan A: Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocyrtes, monocytes and mast cells.

    J Allergy Clin Immunol 1986, 78:914-918. PubMed Abstract | Publisher Full Text OpenURL

  19. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP: TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction.

    J Allergy Clin Immunol 2002, 109:694-700. PubMed Abstract | Publisher Full Text OpenURL

  20. Sabroe R, Poon E, Orchard G, Lane D, Francis D, et al.: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-Fcepsilon or anti-IgE autoantibodies.

    J Allergy Clin Immunol 1999, 103:484-493. PubMed Abstract | Publisher Full Text OpenURL

  21. Peters M, Schroeter A, Kephard G, Gleich G: Localization of eosinophil granule major basic protein in chronic urticaria.

    J Invest Dermatol 1983, 81:39-43. PubMed Abstract | Publisher Full Text OpenURL

  22. Smith CH, Kepley C, Schwartz LB, Lee TH: Mast cell number and phenotype in chronic idiopathic urticaria.

    J Allergy Clin Immunol 1995, 96:360-4. PubMed Abstract | Publisher Full Text OpenURL

  23. Grattan CE, Boon A, Eady R, Winkelmann R: The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions.

    Int Arch Allergy Immunol 1990, 93:198-204. Publisher Full Text OpenURL

  24. Kaplan A: Chronic urticaria: pathogenesis and treatment.

    J Allergy Clin Immunol 2004, 114:465-474. PubMed Abstract | Publisher Full Text OpenURL

  25. Grattan CE, Winkelmann RK, Leiferman KM: Eosinophil major basic protein in autologous serum and saline skin tests in chronic idiopathic urticaria.

    Br J Dermatol 1997, 136:132-148. PubMed Abstract | Publisher Full Text OpenURL

  26. Asero R, Tedeschi A, Lorini M, Gerosa M, Meroni P, Riboldi P: Circulating stem cell factor in patients with chronic idiopathic urticaria.

    Ann Allergy Asthma Immunol 2003, 91:79-81. PubMed Abstract | Publisher Full Text OpenURL

  27. Tedeschi A, Lorini M, Asero R: No evidence of increased serum substance P levels in chronic urticaria patients with and without demonstrable circulating vasoactive factors.

    Clin Exp Dermatol 2005, 30:171-175. PubMed Abstract | Publisher Full Text OpenURL

  28. Tedeschi A, Lorini M, Suli C, Asero R: Serum interleukin-18 in patients with chronic ordinary urticaria: association with disease activity.

    Clin Exp Dermatol 2007, 32:568-570. PubMed Abstract | Publisher Full Text OpenURL

  29. Asero R, Tedeschi A, Riboldi P, Cugno M: Plasma of chronic urticaria patients shows signs of thrombin generation and its intradermal injection causes wheal-and-flare reaction much more frequently than autologous serum.

    J Allergy Clin Immunol 2006, 117:1113-1117. PubMed Abstract | Publisher Full Text OpenURL

  30. Asero R, Tedeschi A, Coppola R, Griffini S, Paparella P, et al.: Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria.

    J Allergy Clin Immunol 2007, 119:705-710. PubMed Abstract | Publisher Full Text OpenURL

  31. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M: Severe chronic urticaria is associated with elevated plasma levels of D-dimer.

    Allergy 2008, 63:176-180. PubMed Abstract | Publisher Full Text OpenURL

  32. Razin E, Marx G: Thrombin-induced degranulation of cultured bone marrow-derived mast cells.

    J Immunol 1984, 133:3282-3285. PubMed Abstract | Publisher Full Text OpenURL

  33. Kido H, Fukusen N, Katunuma M, Morita T, Iwanaga S: Tryptase from rat mast cells converts bovine prothrombin to thrombin.

    Biochem Biophys Res Commun 1985, 132:613-619. PubMed Abstract | Publisher Full Text OpenURL

  34. Asero R, Madonini E: Bronchial hyperresponsiveness is a common feature in patients with chronic urticaria.

    J Investig Allergol Clin Immunol 2006, 16:19-23. PubMed Abstract OpenURL

  35. Tedeschi A, Cottini M, Asero R: Simultaneous occurrence of chronic autoimmune urticaria and non-allergic asthma: a common mechanism?

    Eur Ann Allergy Clin Immunol 2009, 41:56-59. PubMed Abstract OpenURL

  36. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R: Expression of tissue factor by eosinophils in patients with chronic urticaria.

    Int Arch Allergy Immunol 2009, 148:170-174. PubMed Abstract | Publisher Full Text OpenURL

  37. Moosbauer C, Morgenstern E, Cuvelier SL, Manukyan D, Bidzhekov K, et al.: Eosinophils are a major intravascular location for tissue factor storage and exposure.

    Blood 2007, 109:995-1002. PubMed Abstract | Publisher Full Text OpenURL

  38. Puccetti A, Bason C, Simeoni S, Millo E, Tinazzi F, et al.: In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation.

    Clin Exp Allergy 2005, 35:1599-1607. PubMed Abstract | Publisher Full Text OpenURL

  39. Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G: The role of human mast cell-derived cytokines in eosinophil biology.

    J Interferon Cytokine Res 2004, 24:271-281. PubMed Abstract | Publisher Full Text OpenURL

  40. Lampinen M, Carlson M, Håkansson LD, Venge P: Cytokine-regulated accumulation of eosinophils in inflammatory disease.

    Allergy 2004, 59:793-805. PubMed Abstract | Publisher Full Text OpenURL

  41. Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, Cugno M: Plasma levels and skin-eosinophil expression of vascular endothelial growth factor (VEGF) in patients with chronic urticaria 2009 May 27.

    , in press.

  42. Breier G, Albrecht U, Sterrer S, Risau W: Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentation.

    Development 1992, 114:521-532. PubMed Abstract | Publisher Full Text OpenURL

  43. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

    Am J Pathol 1995, 146:1029-1039. PubMed Abstract | PubMed Central Full Text OpenURL

  44. Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F: Human peripheral blood eosinophils induce angiogenesis.

    Int J Biochem J Biol 2005, 37:628-636. Publisher Full Text OpenURL

  45. Bhattacharyya SP, Drucker I, Reshef T, Kirshenbaum AS, Metcalfe DD, Mekori YA: Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact.

    J Leukoc Biol 1998, 63:337-341. PubMed Abstract | Publisher Full Text OpenURL

  46. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA: Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha.

    J Immunol 2001, 167:4008-4016. PubMed Abstract | Publisher Full Text OpenURL

  47. Confino-Cohen R, Aharoni D, Goldberg A, Gurevitch I, et al.: Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with chronic idiopathic urticaria.

    J Allergy Clin Immunol 2002, 109:349-356. PubMed Abstract | Publisher Full Text OpenURL